{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:04:14Z","timestamp":1765184654159,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.clinthera.2006.01.016","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T07:13:20Z","timestamp":1147158800000},"page":"204-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms"],"prefix":"10.1016","volume":"28","author":[{"given":"Gary W.","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.01.016_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V","article-title":"Basic biology and clinical application of specific cyclooxygenase-2 inhibitors","volume":"43","author":"Crofford","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2006.01.016_bib2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.clinthera.2006.01.016_bib3","first-page":"530","article-title":"Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz","year":"2002","journal-title":"J Fam Pract."},{"key":"10.1016\/j.clinthera.2006.01.016_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/joca.2001.0510","article-title":"Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen","volume":"10","author":"Makarowski","year":"2002","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.clinthera.2006.01.016_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-200210000-00011","article-title":"Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis","volume":"14","author":"Sikes","year":"2002","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.clinthera.2006.01.016_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2036.2004.02118.x","article-title":"Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib","volume":"20","author":"Goldstein","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2006.01.016_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2036.2005.02383.x","article-title":"Meta-analysis: Upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis","volume":"21","author":"Eisen","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2006.01.016_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1572-0241.2005.40701.x","article-title":"Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis","volume":"100","author":"Rabeneck","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2006.01.016_bib9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/41.9.1008","article-title":"Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen","volume":"41","author":"Bensen","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2006.01.016_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/rheumatology\/keg359","article-title":"Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial","volume":"42","author":"Pavelka","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2006.01.016_bib11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","article-title":"Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis","volume":"330","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.01.016_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study","volume":"165","author":"Johnsen","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2006.01.016_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.01.016_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.mjt.0000127360.23508.04","article-title":"Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis","volume":"11","author":"White","year":"2004","journal-title":"Am J Ther."},{"key":"10.1016\/j.clinthera.2006.01.016_bib15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5223(03)00125-9","article-title":"Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery","volume":"125","author":"Ott","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clinthera.2006.01.016_bib16","series-title":"Presented at: American College of Cardiology Annual Scientific Session","article-title":"Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery","author":"Whelton","year":"2005"},{"author":"Jenkins","key":"10.1016\/j.clinthera.2006.01.016_bib17"},{"key":"10.1016\/j.clinthera.2006.01.016_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.01.016_bib19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinthera.2006.01.016_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/rheumatology\/XXII.suppl_1.48","article-title":"The assessment of disability: From first to future principles","volume":"22","author":"Fries","year":"1983","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.01.016_bib21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.clinthera.2006.01.016_bib22","doi-asserted-by":"crossref","first-page":"199A","DOI":"10.1016\/S0895-7061(03)00618-6","article-title":"Hypertension and edema rates in 6,717 patients for the new COX-2 inhibitor valdecoxib versus the conventional, nonselective NSAIDs and placebo (P-446)","volume":"16","author":"Whelton","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2006.01.016_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","article-title":"Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor","volume":"7","author":"Whelton","year":"2000","journal-title":"Am J Ther."},{"key":"10.1016\/j.clinthera.2006.01.016_bib24","first-page":"S31","article-title":"COX-2-specific inhibitors and the kidney: Effect on hypertension and oedema","volume":"20","author":"Whelton","year":"2002","journal-title":"J Hypertens Suppl."},{"key":"10.1016\/j.clinthera.2006.01.016_bib25","first-page":"S406","article-title":"Cardiovascular safety of valdecoxib: A meta-analysis of 19 clinical studies in 12,000 patients","volume":"52","author":"Williams","year":"2005","journal-title":"Arthritis Rheum."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:34Z","timestamp":1758962854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0149291806000300"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.01.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}